Literature DB >> 1390342

Stage I seminoma of the testis: is post-orchidectomy surveillance a safe alternative to routine postoperative radiotherapy?

S Ramakrishnan1, A E Champion, M S Dorreen, M Fox.   

Abstract

Experience with the management of 128 patients with Stage I testicular seminoma over a 10-year period, 1980-1989, is presented. Fifty-six patients were treated with post-orchidectomy radiation therapy and 72 patients were put on surveillance. Patients thought to be at higher risk of relapse were generally treated with radiotherapy. There have been no tumour related deaths in this series; 5.4% of the irradiated group and 18% of patients on surveillance have relapsed to date. All relapses have been salvaged with further therapy and are currently in complete remission. In this interim analysis, surveillance appears to be a safe alternative to adjuvant radiation therapy provided regular, prolonged follow-up can be ensured. Surveillance is, however, time consuming and resource demanding, and should be undertaken only as part of a formal clinical study. Adjuvant post-orchidectomy radiotherapy should be considered the treatment of choice until further long-term data are available.

Entities:  

Mesh:

Year:  1992        PMID: 1390342     DOI: 10.1016/s0936-6555(05)81100-8

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  5 in total

1.  Canadian consensus guidelines for the management of testicular germ cell cancer.

Authors:  Lori Wood; Christian Kollmannsberger; Michael Jewett; Peter Chung; Sebastian Hotte; Martin O'Malley; Joan Sweet; Lynn Anson-Cartwright; Eric Winquist; Scott North; Scott Tyldesley; Jeremy Sturgeon; Mary Gospodarowicz; Roanne Segal; Tina Cheng; Peter Venner; Malcolm Moore; Peter Albers; Robert Huddart; Craig Nichols; Padraig Warde
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

Review 2.  Testicular germ cell tumors: pathogenesis, diagnosis and treatment.

Authors:  Christian Winter; Peter Albers
Journal:  Nat Rev Endocrinol       Date:  2010-11-30       Impact factor: 43.330

Review 3.  Clinical stage I seminoma: the case for surveillance.

Authors:  Nathan Lawrentschuk; Neil Fleshner
Journal:  World J Urol       Date:  2009-06-11       Impact factor: 4.226

Review 4.  Treatment of stage I testicular germ-cell tumors.

Authors:  Jorge Aparicio; J R Germà
Journal:  Med Oncol       Date:  2006       Impact factor: 3.738

5.  Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance.

Authors:  Peter Chung; Gedske Daugaard; Scott Tyldesley; Eshetu G Atenafu; Tony Panzarella; Christian Kollmannsberger; Padraig Warde
Journal:  Cancer Med       Date:  2014-09-19       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.